Trial Profile
An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Allantoin (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors Amicus Therapeutics; Scioderm
- 06 Apr 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 03-Sep-2018), according to European Clinical Trials Database record.
- 28 Sep 2018 Status changed from active, no longer recruiting to discontinued.
- 21 Sep 2018 This trial was discontinued in Austria (end date: 2018-06-04), according to European Clinical Trials Database.